All In Biotech

Free tool

FAERS Monitor: Oraqix

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021451 or its brand name (Oraqix, Lidocaine, Prilocaine). Reports on generic versions are filed under their own applications.

Reports

1,450

Serious

825

57% of reports

Hospitalization

456

Death reported

130

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue160
  • nausea131
  • diarrhoea110
  • off label use99
  • vomiting85
  • dyspnoea74
  • pyrexia73
  • product dose omission issue72
  • death69
  • headache69
  • dizziness68
  • pain66
  • pneumonia65
  • cough63
  • drug ineffective58

Reports by year received

View as table
YearReports
20042
20051
20064
20071
20081
20092
20106
20113
20123
201312
201414
201532
201644
201756
201896
2019129
2020110
202198
2022129
2023144
2024152
2025226
2026185

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,709 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product dose omission issueSignal723.62.8131
coughSignal633.32.698
pyrexiaSignal733.12.4101
fatigueSignal1603.02.6217
pneumoniaSignal652.92.381
vomitingSignal852.62.186
diarrhoeaSignal1102.52.198
nauseaSignal1312.42.0110
dizziness682.01.633
dyspnoea741.91.531
off label use991.61.425
headache691.61.315
pain661.61.213
death691.20.91
drug ineffective580.60.512

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.